SI BONE : August 2023 Investor Presentation

Corporate Overview

August 2023

Safe Harbor Statement

This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on SI-BONE's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. Risks to SI-BONE's results include the company's ability to introduce and commercialize new products and indications, its ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices, its ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's devices. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filings on Form 10-K and Form 10-Q, and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors". SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

2

Identifying Unmet Clinical Needs in the Sacropelvic Space

Innovation	Evidence	Education	Commercialization
3 Differentiated Products	2 Randomized Controlled Trials	3,000+ WW Surgeons 1	85 Territory Managers
74 WW Patents	120+ Peer-reviewed Publications	85,000+ Procedures Performed 2	150+ CSS and Agents

Market Leader >$3B Opportunity

Breakthrough Products

Differentiated Health Economics

Scalable Infrastructure

Note: As of June 30, 2023.

1. Trained and performed at least one procedure since inception of the company.
2. Since inception.

3

Large Addressable Markets with Attractive Fundamentals

Pelvic Trauma 5	60,000	$0.3 Billion

~470,000	Adult Deformity 3+ Degenerative Spine 4	130,000	$1.0 Billion
Target U.S Annual	Pelvic Fixation

Procedures 1

> $3 Billion	SI-Joint2
Total U.S. Addressable	$2.4 Billion
280,000

Market 1

1. Management estimate for existing and potential products in 2024. Total addressable market defined as target case volume x Current ASP.
2. Sources: Jensen M, Brant-Zawadzki M, Obuchowski N, et al. Magnetic Resonance Imaging of the Lumbar Spine in People Without Back Pain. N
   Engl J Med. 1994;331:69-116.; Bernard 1987, Schwarzer 1995, Maigne 1996, Irwin 2007,Sembrano 2009.; INSITE RCT data: 5 years in pain and 31% of patients screened were eligible for surgery.; 4. 1.2M therapeutic injections per year with average patient in 5 years of pain = ~280K cases
3. 30K target procedures; 70K Deformity Procedures (Source: U.S.2020 Wallstreet Report) less Pediatric Procedures
   (Source:www.hopkinsmedicine.org.)
4. 100K target procedures: 400K Lumbar Fusion Procedures (Source: 2020 Wallstreet Report); 25% procedures are L4-S1 and L5-S1 (Source: Orthopedic Network News, October 2020)

Target U.S. Annual	Total U.S. Annual
Procedures	Addressable Market

5. US Fragility FX TAM: 136K Incidence x 40% surgical candidates = 54K; High Energy FX TAM: 6K Pelvic Trauma Surgeries = 6K Source: Management estimates based on internal research; Melton et al (1981). Epidemiologic features of pelvic fractures. Clin Orthop Relat Res.; Rommens et al (2017). Fragility fractures of the pelvis. JBJS; Demetriades et al (2002). Pelvic fractures with abdominal injuries. J Am Coll Surg)

4

Strong Demand Momentum in the Second Quarter 2023

1. REVENUE ($M)

$33.3

U.S. REVENUE

($M)

$31.2

U.S. REVENUE GROWTH

(y/y)

31%

$25.6

$23.8

18%

2Q222Q23

2Q222Q23

2Q222Q23

5